ArticleNeurology and therapy2024

Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.

Shoichiro Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.